Notable Labs Inc.
Notable Labs, Ltd., a clinical-stage platform therapeutics company, develops predictive precision medicines for patients with cancer. The company, through its proprietary Predictive Precision Medicines Platform (PPMP), bio-simulates a cancer treatment and predicts, whether or not the patient will clinically respond to their actual treatment. Its PPMP is designed to identify and select clinically … Read more
Notable Labs Inc. (NTBL) - Total Liabilities
Latest total liabilities as of June 2024: $3.82 Million USD
Based on the latest financial reports, Notable Labs Inc. (NTBL) has total liabilities worth $3.82 Million USD as of June 2024.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Notable Labs Inc. - Total Liabilities Trend (2019–2023)
This chart illustrates how Notable Labs Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Notable Labs Inc. Competitors by Total Liabilities
The table below lists competitors of Notable Labs Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ashtead Technology Holdings PLC
LSE:AT
|
UK | GBX188.60 Million |
|
BLE Kedros R.E.I.C.
AT:BLEKEDROS
|
Greece | €26.81 Million |
|
SINGAPORE AIRLINES - Dusseldorf Stock Exchang
DU:SIA1
|
Germany | €26.84 Billion |
|
CONTACT ENERGY
BE:BZB
|
Germany | €3.59 Billion |
|
BOLLORE (BOP.SG)
STU:BOP
|
Germany | €26.84 Billion |
|
LIBERTY INT QVC-A (LB3A.SG)
STU:LB3A
|
Germany | €10.29 Billion |
Liability Composition Analysis (2019–2023)
This chart breaks down Notable Labs Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Notable Labs Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Notable Labs Inc. (2019–2023)
The table below shows the annual total liabilities of Notable Labs Inc. from 2019 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $4.43 Million | -89.58% |
| 2022-12-31 | $42.48 Million | -31.96% |
| 2021-12-31 | $62.43 Million | +478.65% |
| 2020-12-31 | $10.79 Million | -16.89% |
| 2019-12-31 | $12.98 Million | -- |